#2026-05320Tıbbi Cihazlar; Radyoloji Cihazları; Kan Işınlayıcılarının Sınıflandırılması
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA is proposing to classify blood irradiator devices into two categories: those used to prevent transfusion reactions (Class II, moderate regulation) and those used to prevent cancer metastasis (Class III, highest regulation). This creates a formal regulatory framework for devices that were previously unclassified. This affects medical device companies making blood irradiators, blood banks, and hospitals. Clearer classification means manufacturers know exactly what FDA requirements they must meet.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Action
Proposed rule.
Obligations
What this law requires
Manufacturers of blood irradiator devices intended to prevent transfusion-associated graft-versus-host disease must submit a premarket notification (510(k)) to the FDA before marketing
Manufacturers of blood irradiator devices intended to prevent metastasis must submit a premarket approval (PMA) application to the FDA before marketing
Blood irradiator devices intended to prevent transfusion-associated graft-versus-host disease must comply with Class II special controls requirements
Blood irradiator devices intended to prevent metastasis must comply with Class III premarket approval requirements to demonstrate reasonable assurance of safety and effectiveness